NCT05109520

Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL

Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL: A FUTURE Substudy

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 867 (actual)
• Sponsor: prof dr Pieter Gillard · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Retrospective multicenter study analyzing data gathered during the FUTURE study (S59342) to assess the effect of using Insulin Glargine 300 U/mL (Gla-300) on measures of diabetes control and quality of life. Of the FUTURE participants, data about the type of insulin the participants used will be gathered. On the basis of these data participants will be divided in two groups (control or investigational). Change in glycemic control and quality of life from before to after the switch to Gla-300 (investigational group) will be compared to the change of glycemic control and quality of life of the FUTURE participants who did not switch to Gla-300 (control group). The FUTURE study was a 24-month during multicenter observational cohort study analyzing data on the use of the Abbott Freestyle Libre in people with diabetes. Data were gathered during standard clinical follow-up, and from questionnaires that were presented to the participants at defined time points.

Conditions

• Type 1 Diabetes

Interventions

Type	Name	Description
DRUG	Insulin Glargine 300 UNT/ML [Toujeo]	Switch during standard routine care to Gla-300.

Timeline

• Start date: 2021-09-08
• Primary completion: 2021-10-14
• Completion: 2021-10-14
• First posted: 2021-11-05
• Last updated: 2022-08-30

Locations

3 sites across 1 country: Belgium